J. Pneumologia vol.28 número3

The use of single agent cetuximab (Erbitux), a monoclonal antibody against the epidermal growth factor receptor (EGFR), demonstrates significant activity in patients

Do conjunto de críticos vindos das gerações anteriores, Fernando Pernes, ainda que nunca se debruçando em concreto sobre o trabalho de Sarmento destes anos nos textos

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung

NA obra de Verdi a voz está mais isolada porque o acompanhamento é mais simples e meramente sustentador, no entanto na obra de Puccini, a orquestra ao tocar

Two-Year data: Infliximab maintains clinical response in pso- riatic arthritis patients – an analysis of the year 2 data from the infliximab multinational psoriatic arthritis

trastuzumab-based treatment and subsequent reintro- duction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor

In our study, EGFR expression was considered positive in 28.6% of the cases and, although there was no statistical significance, we found a higher rate of expression in tumors

cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of